Thermal ablation (TA) is an attractive treatment for oncology, heart arrhythmias or chronic pain. It offers shorter hospital stays, faster recovery and less complications than surgery. However, specialists are blind regarding target tissue destruction or collateral damage and high failure rates (e.g. recurrence) or overtreatment are common. TechsoMed has developed BioTrace™, the first real-time monitoring and control software for ablation. It interfaces with ultrasound devices to provide AI-guided image analysis and accurate prediction of tissue damage after 24 hrs (done today with CT or MRI). It has been initially validated for liver tumor ablation (oncology) and now it needs to be optimized and exhaustively validated in clinical trials to reach certification in Europe (CE), USA (FDA) and Japan (PMDA). Other applications of the system (e.g. cardiovascular TA) will gradually scale-up the technology. For market deployment, robust partnerships with ultrasound/ablation devices manufacturers (currently Phillips, GEH, Siemens or J&J.) need to be established.